M&A Closing Conditions: Why Deals Fail at the Finish Line
Signing a definitive purchase agreement is not the same as closing a transaction. That distinction, obvious in theory, carries enormous practical consequences for every party at the table. Between the moment a deal is announced and the moment consideration changes hands, a transaction remains contingent, conditional, and vulnerable. M&A closing conditions are the contractual provisions that determine whether a signed deal becomes a completed one, and when they go unsatisfied, years of negotiation, due diligence, and capital allocation can unwind in days.
The gap between signing and closing can span anywhere from a few weeks on a simple private deal to eighteen months or longer on a cross-border transaction requiring multi-jurisdictional regulatory clearance. Data from deal-tracking sources consistently indicate that a meaningful share of announced transactions, estimates frequently cited in legal and academic literature range from 5% to 10% of signed deals, never reach the closing table. In dollar-weighted terms, the figure is even more significant, because the largest, most complex transactions carry the heaviest conditional burdens. A single failed megadeal represents not just lost transaction fees but misallocated strategic capital, disrupted operations, and reputational damage that can define the principals for years.
What makes M&A closing conditions particularly consequential is that they are negotiated before the stresses that will ultimately test them are known. Parties draft closing conditions during a period of relative optimism, immediately after reaching commercial agreement, and the language they select determines who bears the risk of every adverse development that follows. A seller that accepts loosely drafted conditions may discover, eighteen months into a regulatory review, that the buyer holds more optionality than the seller ever intended to grant. A buyer that accepts an aggressive no-financing-out posture may find itself legally obligated to close a deal its lenders have walked away from.
The structure of M&A closing conditions also shapes deal behavior in ways that extend well beyond the contract itself. Buyers that retain broad walk rights face reduced pressure to accelerate regulatory filings. Sellers that accept indefinite outside date extensions lose negotiating leverage with each passing month. Understanding the mechanics of closing conditions is therefore not a post-signing concern; it is a pre-signing strategic imperative that should inform every major term agreed from the letter of intent forward. For a grounding in how closing conditions fit within the full transaction timeline, the M&A process step-by-step overview provides essential context on the sequential phases that precede this critical stage.
Anatomy of a Closing Conditions Framework
At their core, M&A closing conditions are contractual provisions that define the state of the world that must exist before either party is legally obligated to consummate a transaction. They are not aspirational targets or best-efforts commitments; they are binary gates. If a condition is not satisfied or validly waived by the party entitled to waive it, the transaction does not close, and the party whose condition has failed typically holds a contractual right to terminate the agreement without liability, subject to any applicable termination fee structure.
In a definitive purchase agreement, whether structured as a stock purchase agreement, asset purchase agreement, or merger agreement, closing conditions occupy their own dedicated article, typically presented in three distinct categories. The first category contains conditions to the buyer’s obligation to close. These protect the acquirer against changes in the target’s business, breaches of the seller’s representations and warranties, regulatory obstacles, and financing failures where a financing condition is included. The second category contains conditions to the seller’s obligation to close, which principally protect the seller against the buyer’s failure to perform its own pre-closing covenants, deliver required documentation, and obtain its own necessary approvals. The third category covers mutual conditions that must be satisfied for either party’s obligations to arise, most commonly the absence of any legal injunction or governmental order prohibiting the transaction and receipt of required regulatory clearances.
This tripartite structure matters because it allocates closing risk asymmetrically and with precision. Conditions in the buyer’s column are assets the seller negotiated away; every walk right granted to a buyer is a corresponding exposure for the seller. The negotiation of which conditions fall into which column, and how broadly or narrowly each condition is drafted, is therefore one of the most consequential exchanges in the entire transaction. A seller that allows the buyer to carry a broad financing condition has effectively granted an option, not signed a purchase agreement.
The conditions framework also interacts directly with the termination provisions of the definitive agreement. Most agreements provide that if a condition fails, the non-breaching party may terminate and, depending on the cause of failure, collect a termination fee or pursue other remedies. The relationship between which condition failed, which party caused the failure, and what remedy follows is governed by cross-references between the conditions article and the termination article that require careful drafting and equally careful reading. For a detailed treatment of how these provisions are structured across the full suite of deal documents, the M&A process diligence and deal documents overview addresses the documentary architecture within which closing conditions operate.
One additional structural point that practitioners often overlook: conditions can be waived unilaterally by the party they protect, but only that party holds the waiver right. A buyer cannot waive a seller-side condition, and a seller cannot waive a buyer-side condition. Mutual conditions generally require the agreement of both parties to waive. This allocation of waiver rights becomes operationally significant in the final days before a scheduled closing, when one party may be pressing to close over the objection of the other, and the question of whether a particular condition has been satisfied, failed, or informally waived through conduct can carry significant legal weight.
The Standard Closing Conditions Every Buyer and Seller Should Know
Every definitive purchase agreement contains a set of baseline M&A closing conditions that appear, in some form, across virtually every transaction regardless of size, sector, or structure. These provisions represent the contractual floor below which no reasonably negotiated deal should fall. While MAC clauses and financing contingencies generate more litigation and more headlines, the standard conditions are where closing disputes most frequently originate in practice, because their language is often treated as boilerplate when it is anything but.
Bring-Down of Representations and Warranties
The most consequential standard condition is the bring-down, which requires that the representations and warranties made by each party at signing remain true and correct as of the closing date. At signing, the seller delivers a comprehensive set of representations covering the accuracy of financial statements, the absence of undisclosed liabilities, the status of material contracts, intellectual property ownership, litigation exposure, employee matters, tax compliance, and dozens of other subjects depending on the target’s business. The bring-down condition effectively asks: are all of those statements still accurate today?
The answer to that question, and whether any inaccuracy rises to the level of a failed condition, turns entirely on the materiality qualifier embedded in the bring-down standard. There are three principal formulations in common use, and the difference between them is not semantic. The most seller-friendly bring-down standard requires that representations be true and correct except where any failure to be true and correct would not constitute, or reasonably be expected to constitute, a material adverse effect on the target. This is a very high threshold; isolated breaches, errors, or changes in circumstance that do not rise to the MAC level cannot block the close. The intermediate standard requires that representations be true and correct in all material respects, which is modestly more buyer-favorable and introduces a standalone materiality threshold that can be applied representation by representation. The most buyer-friendly formulation requires that the representations be true and correct in all respects, qualified only by a de minimis carve-out, which allows far less deterioration before a buyer can claim a failed condition.
Experienced deal counsel pay particular attention to which standard applies to representations that already contain materiality qualifiers in their substantive language. Applying a bring-down standard of “true and correct in all material respects” to a representation that is already drafted with a materiality qualifier results in a double materiality scrape problem: the buyer must prove not only that the underlying fact is not materially accurate, but also that the inaccuracy is itself material. Most sophisticated buyers negotiate a materiality scrape in the bring-down context, eliminating or disregarding the internal materiality qualifiers when testing whether the representations remain true and correct.
Performance of Pre-Closing Covenants
Alongside the bring-down, virtually every definitive agreement conditions closing on each party’s performance of its pre-closing covenants in all material respects. For the seller, these covenants principally govern how the business is operated in the interim period between signing and closing. The standard formulation requires the seller to operate the business in the ordinary course consistent with past practice and to refrain from taking a specified list of significant actions without buyer consent, including incurring material indebtedness, making acquisitions, disposing of assets above a specified threshold, granting new equity awards, or entering into material contracts outside the ordinary course.
The practical tension in interim operating covenants is significant. A seller’s management team, facing competitive markets and operational decisions that cannot be deferred for months, often finds the buyer consent requirement burdensome and occasionally unworkable. When a seller takes an action that arguably falls outside the ordinary course without obtaining buyer consent, the buyer may claim a failed covenant condition at closing even if the underlying action caused no financial harm to the target. Courts have generally required buyers to demonstrate that a covenant breach was not cured and was of some consequence before permitting termination on this basis, but the precise drafting of the covenant and the materiality qualifier attached to the performance condition determine the outcome in close cases.
Absence of Legal Injunctions and Governmental Orders
Both parties’ obligations to close are conditioned on the absence of any law, injunction, judgment, or order issued by a court or governmental authority that prohibits, restrains, or makes illegal the consummation of the transaction. This mutual condition, sometimes called the no-injunction condition, is essentially non-negotiable and reflects the practical reality that neither party can be compelled to close a transaction that a court has ordered to be halted. Injunctions blocking M&A transactions arise most commonly in the antitrust context, where the Department of Justice or Federal Trade Commission seeks to enjoin a merger pending review, and in the shareholder litigation context, where a target’s stockholders challenge the transaction on fiduciary duty grounds.
The no-injunction condition interacts importantly with the regulatory clearance conditions discussed later in this article. A transaction that has cleared its Hart-Scott-Rodino waiting period but subsequently faces a preliminary injunction from a federal court in an antitrust challenge remains blocked at the closing gate. The distinction between regulatory clearance and absence of a judicial order is therefore not redundant; each addresses a different mechanism by which a governmental actor can obstruct a close.
Required Third-Party Consents
Many transactions require consent from third parties as a condition to closing: lenders whose credit agreements contain change-of-control provisions, counterparties to material contracts with assignment restrictions, joint venture partners with preferential rights, and landlords whose leases require approval of a change of ownership. These consents are typically listed on a schedule to the agreement, and the closing condition is satisfied only when the scheduled consents have been obtained.
The negotiation around consent conditions involves two interrelated questions. First, which consents are material enough to be elevated to a closing condition, as opposed to treated as a pre-closing obligation that the seller must use reasonable best efforts to obtain but whose failure does not itself block closing? Second, what standard of effort does the seller owe in pursuing the listed consents? Sellers typically resist allowing a counterparty’s commercial obstruction or opportunism to give the buyer a termination right, and will push to limit the consent schedule to genuinely deal-critical approvals while accepting only a reasonable best efforts obligation for the remainder.
Delivery of Closing Deliverables
The final category of standard M&A closing conditions covers the mechanics of the closing itself: the delivery by each party of the executed documents, officer certificates, resolutions, and other items required to consummate the transaction. For the seller, typical deliverables include a bring-down certificate from an authorized officer certifying the accuracy of the representations and the performance of the covenants, executed transfer documents, payoff letters for any indebtedness being retired at closing, and releases of liens. For the buyer, deliverables include the closing date purchase price payment, an officer bring-down certificate, and any ancillary agreements the parties have agreed to enter into simultaneously at closing.
Failure to deliver required closing documents is technically a failed condition, and in extreme cases a party has attempted to use a documentation dispute to block a close it no longer wished to complete. For this reason, well-drafted agreements specify the form of each deliverable with precision, often attaching forms as exhibits, and provide a mechanism for waiving minor documentation deficiencies that do not affect the substance of the transaction.
Understanding these baseline conditions in their full technical detail, not just as a checklist, is essential for any party entering a significant M&A process. The advisory context within which these provisions are negotiated matters as much as the legal drafting. Windsor Drake’s M&A advisory services address the full range of closing risk considerations that arise from the earliest stages of a transaction through the closing table.
Material Adverse Change Clauses: Definition, Scope, and Carve-Outs
Among all M&A closing conditions, the material adverse change clause, referred to interchangeably as a MAC or MAE (material adverse effect) clause, is the most litigated, most negotiated, and most misunderstood. Its function appears simple: it permits the buyer to terminate the agreement if the target’s business has suffered a sufficiently severe deterioration between signing and closing. In practice, the MAC clause is a finely calibrated allocation of risk whose enforceability depends almost entirely on how it was drafted and what the courts of the governing jurisdiction have said about comparable language.
Defining the MAC: Structure and Drafting Conventions
A MAC clause typically operates in two places within a definitive purchase agreement. It appears as a defined term, “Material Adverse Effect” or “Material Adverse Change,” and that definition does the substantive work. It also appears as a qualifier in the bring-down condition, so that the buyer cannot terminate solely because a representation is inaccurate unless that inaccuracy would constitute, or reasonably be expected to constitute, a material adverse effect on the target. The buyer that wants a broad MAC right therefore needs to secure both a broad definition and a bring-down standard that references it.
The definition itself is typically constructed in three layers. The first layer sets out the general standard: any event, change, occurrence, circumstance, or development that has had, or would reasonably be expected to have, a material adverse effect on the business, financial condition, results of operations, or assets of the target and its subsidiaries, taken as a whole. The second layer introduces carve-outs: categories of events that are explicitly excluded from the MAC definition regardless of their actual impact on the target. The third layer, present in buyer-favorable agreements, contains a disproportionate impact exception that reinstates excluded events within the MAC definition to the extent they affect the target disproportionately relative to other participants in the target’s industry.
Each layer is negotiated, and each word carries consequences. “Reasonably be expected to have” introduces a forward-looking component that allows a buyer to claim MAC based on anticipated deterioration, not just actual results. “Taken as a whole” requires that the effect be assessed across the consolidated enterprise rather than isolated in a single subsidiary or business unit. “Business, financial condition, results of operations, or assets” is sometimes expanded to include “prospects,” a seller-adverse addition that the Delaware courts have generally viewed with skepticism as a basis for MAC invocation.
Standard Carve-Outs and the Allocation of Systemic Risk
The carve-out architecture is where the real economic negotiation occurs. Sellers push for broad carve-outs that remove systemic and market-wide risks from the MAC definition, on the theory that a buyer should not be permitted to walk away from a deal simply because the external environment deteriorated, particularly when the buyer accepted that environment when it signed. The standard carve-out list in a seller-favorable agreement typically excludes changes in general economic conditions; changes in the financial markets, including interest rates and currency exchange rates; changes affecting the industry in which the target operates; changes in applicable law or accounting standards; acts of war, terrorism, natural disasters, or other force majeure events; changes resulting from the announcement of the transaction itself; and, in agreements drafted post-2020, pandemics and public health emergencies, including any worsening of conditions that existed at signing.
The pandemic carve-out deserves particular attention because it illustrates how market events reshape standard drafting conventions. Prior to March 2020, most MAC definitions did not contain explicit pandemic language; force majeure and general economic condition carve-outs were considered sufficient. The practical ambiguity that arose in spring 2020, when numerous buyers attempted to invoke MACs based on COVID-19’s impact on target businesses, drove a rapid evolution in drafting practice. By late 2020, pandemic and epidemic carve-outs had become routine in virtually every institutional purchase agreement, and sellers began pushing not just for the carve-out but for language expressly acknowledging that the pandemic’s effects were known at signing, which strengthens the argument that any continued deterioration falls within the excluded category.
The disproportionate impact exception to these carve-outs is the buyer’s primary tool for recapturing risk that the carve-outs would otherwise allocate to the seller. If a general macroeconomic downturn devastates the target’s business at twice the rate it affects the target’s industry peers, the buyer argues that the disproportionate impact exception reinstates the downturn within the MAC definition, notwithstanding the general economic conditions carve-out. The drafting battleground in this exception centers on how to define the comparison group, what “disproportionate” means in quantitative terms, and who bears the burden of demonstrating disproportionality.
Delaware Precedent: Akorn and AB Stable
Because the vast majority of significant M&A transactions are governed by Delaware law and litigated in the Delaware Court of Chancery, the court’s MAC jurisprudence effectively sets the standard against which all MAC drafting is measured. Two decisions in particular have defined the modern framework.
In Akorn, Inc. v. Fresenius Kabi AG, decided in October 2018, the Delaware Court of Chancery found for the first time in its history that a buyer had validly invoked a MAC clause to terminate a signed merger agreement. The court’s analysis is instructive on multiple levels. Fresenius established that a MAC had occurred by demonstrating that Akorn’s business had suffered a dramatic and sustained deterioration in financial performance, with year-over-year revenue declines exceeding 25% across multiple quarters, that was disproportionate to the pharmaceutical industry’s general performance. Critically, the court also found that Akorn had engaged in regulatory misconduct that independently breached its representations and satisfied the buyer’s termination rights on those grounds as well. The Akorn decision established that MAC clauses are not dead letters, but it also confirmed the extraordinarily high evidentiary threshold a buyer must clear: the deterioration must be material, durationally significant rather than a short-term fluctuation, and causally attributable to the target rather than to excluded systemic events.
The court’s analysis in AB Stable VIII LLC v. MAPS Hotels and Resorts One LLC, decided in November 2020, addressed a different dimension of MAC risk with direct relevance to M&A closing conditions in the post-pandemic environment. MAPS Hotels had agreed to acquire a portfolio of luxury hotels from AB Stable. When the COVID-19 pandemic devastated hotel operating metrics, the buyer attempted to invoke the MAC clause. The Chancery Court found that the pandemic’s impact did not constitute a MAC because the agreement’s force majeure and industry-wide carve-outs covered it, and because the disproportionate impact exception was not satisfied. However, the court found independently that the seller had breached its ordinary course covenant by taking extraordinary measures in response to the pandemic, including closing hotels entirely and terminating employees, without obtaining buyer consent. The buyer was permitted to terminate, not on MAC grounds, but on covenant grounds. AB Stable is therefore as much a lesson about interim operating covenants as it is about MAC drafting; it demonstrates that in structuring M&A closing conditions, the interaction between the MAC clause and the ordinary course covenant can produce outcomes that neither party anticipated at signing.
The Buyer-Seller Spectrum in MAC Negotiations
Mapping where a proposed MAC definition sits on the buyer-seller spectrum requires analyzing the definition holistically rather than provision by provision. A seller-favorable MAC definition features a broad carve-out list with specific pandemic and public health language, a narrow or absent disproportionate impact exception, a high bring-down standard that references the MAC definition rather than a standalone materiality test, and a forward-looking standard that requires a “reasonable expectation” of material adverse effect rather than mere possibility. A buyer-favorable definition inverts most of these features: narrow carve-outs, a robust disproportionate impact exception, inclusion of “prospects” in the definition, and a bring-down standard that applies MAC as a floor rather than the exclusive test.
The valuation implications of where a MAC clause lands are direct and significant. A seller accepting buyer-favorable MAC language is effectively granting the buyer an option to reprice or exit the deal if business conditions deteriorate, which means the agreed purchase price includes a discount for the optionality extended to the buyer. Properly accounting for this contingent pricing dynamic requires rigorous deal economics analysis; Windsor Drake’s business valuation and deal economics resources address how MAC exposure affects deal pricing and risk allocation in practice.
Financing Contingencies: Committed Capital Versus Conditional Capital
Of all the M&A closing conditions that can derail a signed transaction, financing contingencies represent the most explicit form of buyer optionality embedded in a purchase agreement. A financing condition is, by its nature, a conditional commitment: the buyer is obligated to close only if the capital required to fund the purchase price materializes on acceptable terms. For sellers, accepting a financing contingency is functionally equivalent to granting the buyer a low-cost exit right, one that can be exercised precisely when deal certainty matters most, because financing markets deteriorate when economic conditions deteriorate, which is also when sellers are least positioned to re-run a process.
The Private Equity Financing Stack
In leveraged buyout transactions, the buyer’s financing obligation is documented across two distinct instruments, each of which can become a point of failure between signing and close. The equity commitment letter, or ECL, is issued by the sponsor’s fund to the acquisition vehicle, committing the fund to contribute a specified equity amount to capitalize the buyer entity at closing, subject to conditions. The debt commitment letter, or DCL, is issued by the arranging banks to the sponsor, committing those institutions to provide the agreed senior secured and, where applicable, mezzanine or second-lien financing, again subject to conditions. These conditions include the satisfaction of the acquisition agreement’s own closing conditions, compliance with certain “SunGard” market flex and material adverse change provisions embedded in the debt commitment itself, and, critically, the absence of a “certain funds” breach by the borrower.
The layered conditionality of a PE financing stack means that a sponsor’s obligation to close under the merger agreement is only as firm as the most restrictive condition in the underlying commitment letters. When credit markets deteriorate, as they did materially in the second half of 2022 when rising rate environments caused leveraged loan markets to seize, arranging banks exercise market flex provisions aggressively, widening spreads, adding original issue discount, and in some cases resisting full syndication in ways that technically preserve their commitment while making the economics punitive. Sponsors facing an unfunded deal in that environment look carefully at whether a deterioration in their target’s business, combined with lender resistance, gives them grounds to terminate under the financing condition before more costly remedies apply.
Reverse Termination Fees as the Price of a Financing Out
Sophisticated sellers who accept financing contingencies from PE buyers do not do so without compensation. The standard market mechanism for pricing financing risk is the reverse termination fee (RTF), sometimes called a reverse break fee, which the buyer agrees to pay the seller if the deal fails because the buyer’s financing does not close. RTFs in private equity transactions have historically ranged from 3% to 6% of aggregate transaction value, with the precise percentage reflecting the seller’s assessment of financing risk and the parties’ relative negotiating leverage at the time of signing.
The critical structural question is whether the reverse termination fee functions as the buyer’s exclusive remedy for a financing failure, capping the seller’s recovery at the fee amount, or whether it serves as a floor below which the seller’s damages cannot fall while leaving specific performance and other remedies available. Sellers consistently push for the latter construct, arguing that a capped RTF simply converts the purchase agreement into a put option priced at the fee amount. Buyers, particularly financial sponsors whose fund economics depend on limiting unlimited liability exposure at the transaction vehicle level, resist vigorously. The resolution of this tension in the definitive agreement determines whether the financing condition is a genuine closing risk or a negotiated exit mechanism with a defined cost.
Strategic Acquirers and Balance Sheet Deals
The financing condition analysis in strategic M&A transactions differs substantially from the PE context. Investment-grade strategic buyers completing acquisitions funded from cash on hand or revolving credit facilities typically do not include a financing condition in the merger agreement at all. These buyers have already demonstrated capital access, their commitment letters from relationship banks are supported by investment-grade balance sheets, and accepting a financing condition would represent a concession sellers almost universally refuse at the letter of intent stage. When a strategic buyer does require acquisition financing, the negotiation focuses on whether the financing condition tracks the debt commitment letter’s conditions precisely, or whether the seller can negotiate a tighter standard requiring the buyer to close even if its lenders fail to fund, leaving the buyer to pursue its lenders separately.
Specific Performance as the Seller’s Primary Defense
The most significant evolution in how sophisticated sellers protect themselves against financing failure is not the reverse termination fee but the specific performance provision. Specific performance clauses, when properly drafted, give the seller the contractual right to compel the buyer to cause its equity commitment to be funded and to close the transaction, rather than simply collecting a monetary termination fee after the deal collapses. The availability of specific performance as a remedy effectively converts the buyer’s closing obligation from a conditional one into a near-absolute one, provided the seller’s own conditions to close are satisfied and the buyer’s financing is available or would be available but for the buyer’s own failure to draw it down.
Delaware courts have generally enforced specific performance provisions in M&A agreements when the drafting is clear, the seller’s conditions are met, and the buyer’s equity commitment letter expressly permits the seller to enforce funding as a third-party beneficiary. The interplay between these provisions is one of the most technically demanding areas of M&A closing conditions drafting, and the outcomes in contested cases often hinge on whether the specific performance right was drafted to survive a financing failure or only to compel closing when financing has already been obtained. For sellers evaluating how to structure these protections within a comprehensive transaction framework, Windsor Drake’s transaction advisory services address the full range of closing condition mechanics from initial term sheet through definitive agreement execution.
Regulatory and Antitrust Clearances as Closing Conditions
For any transaction of meaningful scale, regulatory and antitrust clearances are not procedural formalities; they are substantive M&A closing conditions that can extend the signing-to-close timeline by a year or more and, in the most contested cases, block a transaction entirely. Unlike MAC clauses or financing contingencies, regulatory conditions are largely non-negotiable in their existence: a deal that triggers mandatory review thresholds must obtain the required clearances before closing, regardless of what the parties prefer. What is negotiable, and what separates well-structured transactions from poorly structured ones, is how regulatory risk is allocated between buyer and seller in the definitive agreement.
Hart-Scott-Rodino Act: The U.S. Antitrust Gateway
The Hart-Scott-Rodino Antitrust Improvements Act of 1976 establishes the primary U.S. antitrust filing obligation. Transactions that exceed the current HSR size-of-transaction and size-of-person thresholds, which the Federal Trade Commission adjusts annually (the transaction-size threshold stood at $119.5 million for the 2024 filing year, with the controlling-person threshold at $478 million), require both parties to file notification with the FTC and the Department of Justice Antitrust Division and observe a mandatory waiting period before closing. The standard waiting period is thirty calendar days, but the reviewing agency may issue a second request for additional information, which resets the clock and in practice extends review by several months. Second requests in competitively sensitive transactions routinely produce timelines of six to twelve months of additional document production, deposition, and economic analysis before the agency reaches a determination.
The substantive standard applied by the reviewing agency is whether the transaction would substantially lessen competition in any relevant market. That assessment turns on market definition, concentration analysis under the Herfindahl-Hirschman Index, theories of competitive harm including unilateral and coordinated effects, and the availability of efficiencies defenses. When the agency concludes that the transaction as proposed is unlawful, it may seek to block the deal outright through a preliminary injunction in federal court, or it may accept a consent decree requiring divestitures of overlapping business lines as a remedial condition to clearance. Divestiture requirements impose their own closing complexity: the parties must identify acceptable divestiture assets, find a buyer for those assets, and in some cases obtain a separate regulatory approval for the divestiture transaction itself, all within the outside date window of the main agreement.
The FTC and DOJ’s approach to merger enforcement has varied materially across administrations. The period from 2021 through 2024 saw notably aggressive enforcement postures from both agencies, with the FTC under Chair Lina Khan litigating challenges to transactions that prior agency leadership might have resolved through consent decrees, and the DOJ Antitrust Division under AAG Jonathan Kanter similarly pursuing full litigation in several high-profile cases. Buyers and sellers negotiating M&A closing conditions during this period were required to assign materially higher probability to protracted regulatory timelines than historical base rates would have suggested. Deal teams that failed to account for this enforcement environment in their outside date structuring and remedies provisions encountered significant problems when reviews extended well beyond their scheduled closing windows.
CFIUS: National Security Review Under FIRRMA
Cross-border transactions involving foreign acquirers, or domestic transactions with foreign co-investors, must evaluate whether the deal triggers review by the Committee on Foreign Investment in the United States. CFIUS operates under the statutory authority of the Foreign Investment Risk Review Modernization Act of 2018, which substantially expanded both the committee’s jurisdiction and its mandatory review categories relative to the prior framework established by the Exon-Florio Amendment of 1988.
Under FIRRMA, certain categories of transactions involving foreign persons are subject to mandatory CFIUS declarations, including acquisitions of TID U.S. businesses, meaning businesses involved in technology, infrastructure, or data with national security implications. A mandatory declaration requires the parties to file a short-form notice with CFIUS at least thirty days before closing, and the committee has thirty days to respond with a clearance, a request for a full notice, or a referral for a full review. A voluntary full notice triggers a thirty-day initial review period, which can be extended to a forty-five-day investigation phase and, in exceptional cases, referred to the President for final determination. The total potential timeline from initial filing to presidential determination, though rarely reached, can span over one hundred days, and the parties must obtain CFIUS clearance before closing regardless of HSR status.
CFIUS has become a decisive M&A closing condition in an expanding range of transactions. The committee’s jurisdiction extends beyond traditional defense and intelligence adjacencies to cover semiconductor manufacturing, critical minerals, agricultural land in proximity to military installations, port operations, telecommunications infrastructure, and companies handling sensitive personal data of U.S. citizens at scale. Deals in these sectors that involve any non-U.S. investor, even a minority financial sponsor with a foreign limited partner base, require careful CFIUS structuring from the earliest stages of deal design. Mitigation agreements, which CFIUS uses as an alternative to outright blocking orders, impose operational restrictions, personnel requirements, and ongoing reporting obligations that can fundamentally alter a buyer’s investment thesis.
EU Merger Control: EC Regulation 139/2004
Transactions that meet the EU merger regulation’s turnover thresholds trigger mandatory pre-closing notification to the European Commission under EC Regulation 139/2004, which operates on a one-stop-shop principle for deals with a Community dimension. The relevant thresholds require combined worldwide turnover exceeding €5 billion and EU-wide turnover of each of at least two parties exceeding €250 million, subject to exceptions for transactions reviewed predominantly in member-state jurisdictions. Below these thresholds, deals may still trigger national merger control filings in individual EU member states, which in practice means managing parallel multi-jurisdictional review processes with varying timelines and substantive standards.
The EC review proceeds in two phases. Phase I is a twenty-five working day initial assessment, extendable to thirty-five working days if remedies are offered. The vast majority of notified transactions, approximately ninety percent historically, clear in Phase I, often with remedies accepted to address minor competitive concerns. Transactions that raise serious doubts about competitive compatibility enter Phase II, a ninety working day in-depth investigation extendable in various circumstances up to one hundred twenty-five working days. Phase II reviews in complex cases, particularly those involving digital markets, pharmaceutical combinations, or transactions with horizontal and vertical effects across multiple product markets, have consumed twelve to eighteen months of elapsed time from notification to final decision. Several high-profile transactions have been blocked outright by the Commission following Phase II review, and others have been abandoned by the parties after the Commission issued a statement of objections signaling likely prohibition.
Sector-Specific Regulatory Approvals
Beyond general antitrust review, many industries impose sector-specific regulatory approvals as mandatory M&A closing conditions. Transactions involving broadcast licenses require FCC approval, and the FCC’s review timeline is notoriously unpredictable, particularly for transactions that attract petitions to deny from public interest advocates or competing broadcasters. Transfers of energy assets, including natural gas pipelines, electric transmission facilities, and wholesale power markets, require FERC approval under the Federal Power Act and the Natural Gas Act, with certain transactions also requiring state public utility commission approvals in each jurisdiction where the target holds assets. Banking transactions require approval from the Federal Reserve, the OCC, or state banking regulators depending on the charter structure of the institutions involved, and those reviews incorporate community reinvestment act assessments and financial stability analyses that add substantive content well beyond pure antitrust scrutiny. Insurance company acquisitions require prior approval from the insurance commissioner of each state where the target is domiciled, a process that can involve multiple simultaneous state filings with varying information requirements and timelines.
Hell-or-High-Water Clauses and the Allocation of Regulatory Risk
Because regulatory risk is largely within the buyer’s control to resolve, sellers have developed a suite of contractual tools to ensure buyers do not treat regulatory conditions as optional or as embedded optionality to abandon a deal. The most aggressive seller-protective mechanism is the hell-or-high-water clause, which obligates the buyer to take all actions necessary to obtain regulatory clearance regardless of cost, including divesting assets, accepting behavioral remedies, and litigating against regulatory challenges through all available appeals. A true hell-or-high-water obligation removes the buyer’s ability to claim that a required divestiture is commercially unacceptable or that litigating the FTC’s preliminary injunction motion is too expensive. Buyers resist these provisions vigorously, particularly in transactions with meaningful antitrust risk, and the negotiated outcome typically lands on a “reasonable best efforts” or “efforts to obtain clearance” standard that requires substantial action but stops short of an obligation to accept any remedy required by a regulator.
Reverse termination fees in the regulatory context function differently from their financing counterpart. A regulatory reverse termination fee compensates the seller if the deal cannot close because required clearances are not obtained within the outside date period. Unlike financing RTFs, which are often structured as the buyer’s exclusive remedy, regulatory RTFs are more frequently combined with retained specific performance rights, because a buyer’s failure to aggressively pursue clearance, rather than a genuine regulatory impasse, is a cognizable breach. Setting the regulatory RTF at a level sufficient to compensate the seller for the full opportunity cost of a failed process, including foregone alternatives during the exclusivity period and operational disruption, is a central element of sell-side M&A transaction structuring that distinguishes well-prepared sellers from those who learn these lessons after signing.
Outside date structuring is the final critical element of regulatory risk allocation in M&A closing conditions. Transactions with meaningful antitrust risk or multi-jurisdictional regulatory requirements should build in initial outside dates of twelve to eighteen months from signing, with extension provisions that allow one or both parties to extend automatically if regulatory conditions have not been satisfied but remain capable of satisfaction. Outside dates that are too compressed relative to realistic regulatory timelines create leverage crises near the deadline, where a buyer facing a pending FTC second request and an approaching outside date can use the time pressure to renegotiate price or terms. Sellers who understand this dynamic negotiate extension mechanics carefully, often tying automatic extensions to the buyer’s obligation to continue pursuing clearance with required efforts and to pay interim extension fees that compensate the seller for the cost of continued uncertainty.
How Sellers Can Protect the Close: Negotiating Leverage and Contract Mechanics
The architecture of M&A closing conditions is not neutral. Left to default market positions, most conditions favor the buyer: broad walk rights, loosely qualified bring-down standards, financing outs, and generous outside date extensions collectively give acquirers multiple paths to exit a transaction that no longer suits them. Sellers who understand this dynamic at the outset, and who treat the negotiation of closing condition mechanics with the same rigor they apply to purchase price, materially improve their probability of reaching the closing table on the terms they agreed.
Tightening the Bring-Down Standard
The first line of seller protection in M&A closing conditions is the bring-down standard itself. Sellers should resist any bring-down formulation that applies a standalone materiality qualifier representation by representation, and should instead push for a MAC-linked standard that requires the buyer to demonstrate a material adverse effect on the business as a whole before any inaccuracy in representations constitutes a failed condition. This distinction carries real consequence: a buyer attempting to invoke a bring-down failure under a representation-by-representation materiality standard needs to prove far less deterioration than one operating under a MAC-linked threshold. Sellers should additionally push back hard on any proposal to include “prospects” in the MAC definition, given the Delaware Court of Chancery’s consistent skepticism toward forward-looking MAC invocations under Akorn and its progeny. The tighter the bring-down standard, the narrower the buyer’s window to manufacture a closing failure out of ordinary business fluctuation.
Specific Performance Rights: Converting a Conditional Commitment into an Obligation
Specific performance is the most powerful tool available to sellers in the M&A closing conditions negotiation, and it is frequently underweighted at the letter of intent stage, where many parties treat it as a downstream documentation detail rather than a foundational commercial term. A properly drafted specific performance provision gives the seller the contractual right to compel the buyer to fund its equity commitment and close the transaction, rather than simply walking away and paying a reverse termination fee. The enforceability of this right in Delaware depends on several conditions being met simultaneously: the seller’s own closing conditions must be satisfied, the buyer’s financing must be available or would be available but for the buyer’s own failure to draw it, and the equity commitment letter must expressly designate the seller as a third-party beneficiary entitled to enforce funding. Sellers should insist that deal counsel verify each of these prerequisites in the drafting of both the merger agreement and the equity commitment letter, because the specific performance right is only as strong as its least carefully drafted supporting document. When structured correctly, specific performance effectively eliminates the buyer’s option to treat the reverse termination fee as a fixed-price exit mechanism.
Limiting Walk Rights and Structuring the Reverse Termination Fee
Sellers should approach every buyer walk right as a negotiated concession, not a market given. Where financing conditions are accepted, the reverse termination fee should be structured not as an exclusive remedy but as a floor, preserving the seller’s right to pursue specific performance and, in cases of willful breach, additional damages above the RTF amount. An RTF-as-exclusive-remedy construct benefits only the buyer; it caps the cost of walking away and effectively converts the purchase agreement into a call option. Sellers with strong process leverage, competitive tension among multiple bidders, or a particularly attractive asset should resist the exclusive remedy framing entirely and insist that specific performance remain available even after the RTF threshold is triggered. Where the market requires accepting an exclusive remedy structure, the RTF percentage should be set at a level that genuinely compensates for the full cost of deal failure, typically toward the upper end of the 3% to 6% range that characterizes institutional PE transactions, rather than at a discount that underprices the optionality being granted.
Interim Operating Covenants as Seller Optionality
The interim operating covenants that govern seller conduct between signing and closing are frequently treated as a buyer-protective mechanism, because they restrict the seller’s operational freedom. Sellers, however, can use the covenant negotiation to preserve meaningful optionality of their own. By narrowing the list of actions requiring buyer consent, building in deemed-consent timelines for routine business decisions that require expedited resolution, and carving out specific categories of ordinary course action that are expressly permitted regardless of their size or novelty, sellers maintain operational agility without triggering a covenant breach that could give the buyer a termination right. The AB Stable decision demonstrated how a seller’s emergency operational responses, absent buyer consent, can become an independent basis for termination even when the MAC clause itself would not have been satisfied. Sellers should negotiate the interim covenants with this precedent in mind, ensuring that reasonable crisis-response measures are pre-authorized rather than left to the buyer’s after-the-fact consent.
Many of the terms that determine a seller’s closing condition protections are first established, at least in outline, at the letter of intent stage, when the parties are still competing for the deal and seller leverage is at its peak. Sellers who defer these negotiations to the definitive agreement phase, assuming the substantive provisions can be improved later, frequently discover that the commercial momentum of a signed LOI, combined with the buyer’s diminished incentive to concede once exclusivity is granted, makes meaningful improvement difficult. Exit readiness planning that anticipates closing condition risks, and builds negotiating strategy around them before the process launches, is the most durable form of closing protection available to any seller.
Real-World Scenarios: When Closing Conditions Are Invoked
Abstract discussions of M&A closing conditions acquire their full weight only when tested against the pressures of an actual transaction. The three scenarios below are drawn from the patterns, mechanics, and dispute dynamics that have characterized real deal failures across the past decade. Each illustrates a distinct failure mode and draws out the legal, financial, and reputational consequences that follow when closing conditions become contested rather than ministerial.
Scenario One: The Leveraged Buyout and the Frozen Debt Market
Consider a mid-market software company that signs a definitive merger agreement with a private equity sponsor in the spring of a given year, at an enterprise value of $1.4 billion, implying a purchase price multiple at the upper end of historical ranges for the sector. The sponsor’s financing stack consists of an equity commitment letter for $420 million and a debt commitment letter from two arranging banks for $980 million in senior secured term loan B and revolving credit facilities. The merger agreement contains a financing condition, a reverse termination fee equal to 4.5% of transaction equity value, and a specific performance provision that the seller’s counsel negotiated to survive a financing failure, subject to the equity commitment being available.
Six months later, the Federal Reserve accelerates its rate-hiking cycle in response to persistent inflation. Leveraged loan markets reprice sharply, and the arranging banks notify the sponsor that the original debt commitment is no longer economically viable at the committed terms. The banks invoke market flex provisions, demanding a 175 basis point increase in the spread and a 2.5-point original issue discount increase, which would increase the sponsor’s all-in cost of debt by approximately $22 million annually and reduce projected equity returns below the fund’s hurdle rate. The sponsor, facing a deal it priced for a different rate environment, begins looking for grounds to terminate.
The sponsor’s counsel examines the debt commitment letter carefully. The standard “SunGard” provisions in the commitment protect the arranging banks’ ability to flex terms, but the commitment itself remains technically outstanding; the banks have not formally withdrawn it. The sponsor then evaluates whether deterioration in the target’s cloud revenue retention metrics, which softened modestly in the preceding quarter, constitutes a MAC sufficient to terminate the merger agreement independently. The target’s retention rate declined from 112% to 106%, a meaningful change but one within the range of ordinary business fluctuation for a company of this profile.
This is precisely the scenario the Akorn standard was designed to address. The sponsor cannot invoke MAC based on a quarter of softened retention metrics absent a showing of dramatic, sustained, and disproportionate deterioration. The financing condition, however, remains available if the buyer can demonstrate that the committed financing is not “available” within the meaning of the specific performance provision. The litigation posture turns on whether the market flex exercise by the banks constitutes an effective withdrawal of committed financing, a question that depends on the precise language of the debt commitment letter and the merger agreement’s definition of “Financing.”
The seller, recognizing the pattern, exercises its specific performance right before the outside date and files in the Delaware Court of Chancery to compel closing. The ensuing litigation is expensive, reputationally damaging for the sponsor, and ultimately resolved through a negotiated price reduction of approximately 8%, costing the seller roughly $112 million in value relative to the signed purchase price. The reverse termination fee, had the seller accepted it as the exclusive remedy, would have returned approximately $30 million, less than thirty percent of the actual value concession extracted through litigation pressure.
The lesson for sellers operating in volatile rate environments is not simply to avoid financing conditions but to ensure the specific performance mechanics are drafted with enough precision to survive exactly this kind of structured ambiguity about whether committed financing remains “available.”
Scenario Two: The Strategic Acquirer and the Deteriorating Target
A publicly traded consumer products company announces a definitive agreement to acquire a privately held specialty nutrition brand for $680 million, a transaction structured as a stock purchase agreement with no financing condition, a MAC-linked bring-down standard, and a twelve-month outside date. The signing-to-close timeline is projected at four to five months, pending HSR clearance and a routine third-party consent from the target’s primary manufacturing contract partner.
In the third month after signing, the target’s management notifies the buyer that its two largest retail distribution partners are restructuring their shelf allocation programs, effective in the next quarter. The target projects that this reallocation will reduce annualized revenue by approximately 18% and EBITDA by approximately 31%, from $62 million to approximately $43 million. The buyer, which priced the acquisition at roughly eleven times trailing EBITDA, now faces an asset worth substantially less than the purchase price under any reasonable valuation methodology. The buyer’s strategic rationale, which centered on acquiring the target’s distribution relationships in precisely those retail channels, has been materially undermined.
The buyer invokes the MAC clause, citing the revenue and EBITDA decline projections as evidence of a material adverse effect on the target’s business, financial condition, and results of operations. The seller disputes the invocation on two grounds. First, the seller argues that a retail shelf reallocation is an industry-wide channel shift affecting multiple specialty nutrition brands, not a target-specific deterioration, and therefore falls within the industry conditions carve-out. Second, the seller argues that forward-looking projections of decline do not constitute a MAC; the actual results have not yet been recorded, and the buyer is attempting to exit a deal based on management’s internal estimates rather than realized performance.
This dispute maps closely onto the analytic framework established by Akorn, which required the buyer to demonstrate that the deterioration was material, durationally significant, and not attributable to excluded causes. Here, the buyer’s MAC argument is strongest if it can establish that the shelf allocation loss is specific to the target’s brand positioning, perhaps because a competitor with a superior reformulated product captured the displaced shelf space, rather than a category-wide contraction. The disproportionate impact exception in the MAC definition is the buyer’s central tool: if the target lost 18% of revenue while the broader specialty nutrition category declined only 3%, the exception may reinstate the industry conditions carve-out risk back within the MAC definition.
The valuation dispute that emerges from this scenario is central to the resolution. Both parties commission competing fairness analyses: the seller’s advisor values the business at $580 to $620 million assuming a temporary distribution disruption and recovery, while the buyer’s advisor values it at $390 to $440 million assuming the channel loss is permanent. The gap between these analyses, roughly $180 to $200 million, reflects genuine uncertainty about whether the distribution disruption is cyclical or structural, a question that no amount of contract drafting can resolve in advance. Sellers in comparable situations benefit from having established a rigorous and defensible pre-signing valuation baseline; Windsor Drake’s business valuation services address how independent valuation analysis creates a documented reference point that can anchor these mid-process disputes and limit the buyer’s ability to reprice unilaterally under MAC pressure.
The transaction ultimately closes at a renegotiated price of $540 million, roughly $140 million below the signed purchase price. Whether the seller could have obtained a better outcome through litigation depends on the specific MAC drafting, but the reputational cost of a contested deal, including the disclosure obligations of the publicly traded buyer and the erosion of management relationships at the target, accelerated the commercial resolution.
Scenario Three: The Cross-Border Deal and the Expiring Outside Date
A European industrial conglomerate announces the acquisition of a U.S. specialty chemicals manufacturer for $2.1 billion. The transaction requires HSR clearance, EC merger notification given the combined parties’ European operations, and CFIUS review triggered by the target’s contracts with U.S. defense-adjacent customers in the specialty coatings segment. The definitive merger agreement sets an initial outside date of fifteen months from signing, with a six-month automatic extension if regulatory conditions remain the sole unsatisfied conditions.
The HSR review closes without a second request after the initial thirty-day waiting period. The EC review, however, enters Phase II after the Commission identifies competitive concerns in the European market for specialty polymer additives, a product line representing approximately 12% of the target’s consolidated revenue. The Phase II investigation proceeds for seven months before the Commission issues a statement of objections. The parties negotiate a divestiture remedy involving the target’s Belgian manufacturing facility and its associated customer contracts, a remedy the Commission accepts conditional on buyer closing. CFIUS, meanwhile, conducts a full review of the target’s defense-related contracts and negotiates a mitigation agreement requiring the buyer to establish a proxy board structure for the relevant U.S. subsidiary, a process that itself takes four months to document and approve.
By the time all regulatory conditions are satisfied, twenty-two months have elapsed since signing. The initial outside date was extended by six months under the automatic extension provision, reaching twenty-one months. The buyer, whose integration planning has consumed substantial executive bandwidth and whose acquisition financing, a committed bridge facility, has been extended twice at increasing cost, is technically in a position to close. The seller, however, has spent nearly two years in operational limbo: unable to pursue alternative strategic transactions, constrained by interim operating covenants from making significant capital allocation decisions, and absorbing the management distraction of prolonged regulatory process.
This scenario illustrates a dimension of M&A closing conditions risk that is often underweighted in deal structuring: the cost to the seller of an extended signing-to-close period even when the transaction ultimately closes. The seller’s board accepted the fifteen-month outside date with a six-month extension in exchange for a modest regulatory reverse termination fee of 3.5% of transaction value, approximately $73.5 million. But the actual cost of the twenty-two month delay, measured in foregone strategic alternatives, management distraction, and operational constraints under the interim covenants, materially exceeded the RTF. A seller that had negotiated extension fees payable monthly after the initial outside date, or a higher regulatory RTF calibrated to a realistic multi-jurisdictional review timeline, would have been meaningfully better compensated for the uncertainty absorbed.
The reputational dynamics in this scenario extend beyond the transaction parties. The Belgian facility divestiture, conducted under time pressure as a condition of EC clearance, was executed at a discount to the facility’s standalone market value because the limited buyer pool for a mid-sized specialty chemicals plant was aware of the seller’s constrained negotiating position. The acquirer’s integration timeline, already eighteen months behind internal projections at closing, contributed to senior management turnover in the acquired business within the first year post-close. These downstream costs are not reflected in the transaction headline price but are part of the complete economic picture of a deal in which M&A closing conditions were not structured to account for the realistic probability and cost of extended regulatory delay.
Closing Conditions Strategy: Building a Deal That Can Actually Close
The three scenarios in the preceding section share a common thread: each failure or near-failure traces back to decisions made before the definitive agreement was signed. MAC disputes, financing collapses, and regulatory delays do not materialize at closing without warning; they develop from risks that were present, and often knowable, at the time parties were negotiating terms. The most effective M&A closing conditions strategy is therefore a pre-signing strategy, one that treats due diligence, contract mechanics, and regulatory pre-assessment as integrated disciplines rather than sequential tasks.
Pre-signing due diligence is the primary defense against failed conditions because it determines the accuracy of the representations that must survive the bring-down. A buyer that identifies deteriorating retention metrics, channel concentration risk, or contingent regulatory exposure during diligence can price those risks, negotiate targeted representations, or walk away with full information before signing. A buyer that closes diligence quickly to maintain deal momentum and then discovers the same issues between signing and closing has no good options: invoking MAC requires clearing an extraordinarily high evidentiary bar, and renegotiating price after signing destroys relationships and invites litigation. Sellers benefit equally from rigorous pre-process diligence, because a target that enters a sale process with audited financials, clean title to its intellectual property, resolved litigation, and documented regulatory compliance gives buyers less surface area to manufacture closing condition failures.
Outside date structuring deserves more analytical attention than most deal teams give it. The outside date is not a deadline; it is a risk allocation mechanism. Setting it too aggressively relative to realistic regulatory timelines creates leverage crises that buyers exploit. Setting it without extension fee mechanics that compensate sellers for delay effectively subsidizes the buyer’s optionality with the seller’s time. Transactions with multi-jurisdictional regulatory exposure should build timelines from the regulatory calendar outward, accounting for realistic Phase II or second request scenarios rather than base case approvals, and should pair any automatic extension with monthly extension fees sufficient to make delay economically neutral for the seller.
Early and proactive engagement with regulators and lenders before signing reduces the variance around these timelines materially. Buyers in transactions with potential antitrust overlap should conduct informal pre-notification outreach with the relevant agency where agency practice permits, to develop a preliminary read on likely review depth before committing to an outside date. Sponsors assembling leveraged financing should stress-test their debt commitment letters against rate scenarios that are worse than current market conditions, not merely current conditions. These actions do not eliminate closing risk, but they convert unknown unknowns into known ones that can be priced and structured around.
The period between signing and closing is an active phase of deal execution, not a waiting room. Sellers must manage interim operating covenants with discipline, documenting consent requests, maintaining ordinary course operating records, and avoiding actions that could later be characterized as covenant breaches even when those actions are commercially sensible. Buyers must advance regulatory filings, maintain lender relationships, and resist the temptation to use the pre-closing period to seek price adjustments that the contract does not support. Both parties benefit from a joint closing checklist process managed by deal counsel, updated regularly, and shared transparently so that no condition failure arrives as a surprise. The M&A process step-by-step framework provides the sequential structure within which this active management discipline operates. For parties seeking experienced guidance on structuring M&A closing conditions that hold from signing through close, Windsor Drake’s M&A advisory services address the full range of transaction execution considerations that determine whether a signed deal becomes a completed one.
